Fide, EzgiYerlikaya, DenizÖz, DidemÖztura, İbrahimYener, Görsev2023-06-162023-06-1620231550-05942169-5202https://doi.org/10.1177/15500594221120723https://hdl.handle.net/20.500.14365/2231Acetylcholinesterase inhibitors (AChE-I) are the core treatment of mild to severe Alzheimer's disease (AD). However, the efficacy of AChE-I treatment on electroencephalography (EEG) and cognition remains unclear. We aimed to investigate the EEG power and coherence changes, in addition to neuropsychological performance, following a one-year treatment. Nine de-novo AD patients and demographically-matched healthy controls (HC) were included. After baseline assessments, all AD participants started cholinergic therapy. We found that baseline and follow-up gamma power analyzes were similar between groups. Yet, within the AD group after AChE-I intake, individuals with AD displayed higher gamma power compared to their baselines (P < .039). Also, baseline gamma coherence analysis showed lower values in the AD than in HC (P < .048), while these differences disappeared with increased gamma values of AD patients at the follow-up. Within the AD group after AChE-I intake, individuals with AD displayed higher theta and alpha coherence compared to their baselines (all, P < .039). These increased results within the AD group may result from a subclinical epileptiform activity. Even though AChE-I is associated with lower mortality, our results showed a significant effect on EEG power yet can increase the subclinical epileptiform activity. It is essential to be conscious of the seizure risk that treatment may cause.eninfo:eu-repo/semantics/closedAccessacetylcholinesterase inhibitors (AChE-I)Alzheimer's disease (AD)EEG power and coherencegamma bandtheta bandalpha bandQuantitative EegCholinesterase InhibitorCholinergic HypothesisFrequency OscillationsEpileptiform ActivitySpectral-AnalysisNucleus BasalisDonepezilMemoryRivastigmineArticle10.1177/155005942211207232-s2.0-85135949714